Akari Therapeutics (NASDAQ:AKTX) Receives New Coverage from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a report released on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Akari Therapeutics Trading Down 13.6 % NASDAQ:AKTX opened at $2.60 on Friday. The company’s 50 day moving average price is $3.01 and […]

Related Keywords

,Nasdaq ,Renaissance Technologies ,Cerity Partners ,Sabby Management ,Akari Therapeutics Company Profile ,Akari Therapeutics Plc ,Zakari Therapeutics ,Get Free Report ,Therapeutics Trading Down ,Akari Therapeutics Daily ,Nasdaq Aktx ,Aktx ,Medical ,Initiated Coverage ,Stocknews Com ,